



PROFICIENCY TESTING REPORT
ISHTM-AIIMS EXTERNAL QUALITY ASSURANCE PROGRAMME
 NABL accredited program as per ISO/IEC 17043:2010 standard
 Organized By Department of Hematology, AIIMS, New Delhi-110029



Duration of stability testing - minimum upto 8 days at ambient temp. after dispatch of specimens

EQAP CODE No. : 2525

Distribution No.: 158-E

Month/Year: December/2022

Instrument ID: RBC04011

Name & Contact No. of PT Co-ordinator: Dr. Seema Tyagi (Prof.), Hematology, AIIMS, Delhi,
 Tel: 9013085730 , E-Mail : accuracy2000@gmail.com

Date of issue & status of the report: 24-01-2023[Final].

CBC and Retic Assessment

Test Parameters	S.No.	Among Lab (Accuracy Testing)						Within Lab (Precision Testing)			
		Your Result 1	Your Result 2	Your Results Sum of 2 Value	Consensus result sum of 2 values (Assigned Value)	Uncertainty of Assigned Values	Z Score	Yours Results Diff. of 2 Values	Consensus Result Diff. of 2 values (Assigned Value)	Uncertainty of Assigned Values	Z Score
WBC x10 ³ /µl	1	7.9	7.8	15.7	15.7	0.0450	0.00	0.1	0.13	0.0080	-0.29
RBC x10 ⁶ /µl	1	3.41	3.41	6.82	6.92	0.0070	-0.54	0	0.03	0.0020	-0.81
Hb g/dl	1	12.3	12.2	24.5	25.1	0.0210	-1.16	0.1	0.1	0.0080	0.00
HCT%	1	39.8	39.7	79.5	78.25	0.1850	0.23	0.1	0.4	0.0250	-1.01
MCV-fl	1	116.8	116.3	233.1	225.5	0.5040	0.53	0.5	0.3	0.0230	0.54
MCH-Pg	1	36	35.8	71.8	72.6	0.0840	-0.42	0.2	0.3	0.0210	-0.34
MCHC-g/dl	1	31	30.7	61.7	63.8	0.1540	-0.43	0.3	0.3	0.0190	0.00
Plt. x10 ³ /µl	1	225	225	450	459	1.62	-0.22	0	5	0.35	-0.96
Retic %	2	10	8	18	29	0.68	-0.52	2	1	0.07	0.90

P.S . Assesment

YOUR REPORT			CONSENSUS REPORT
DLC%	3	Nrbcs=0 , Poly=3 L=96, E=1, Mono/Promono=0 , B1=0 P.M.=0, Mye=0, Meta=0, Other=Smudge cells seen	Blast: 65-87, Poly: 5-10, Lympho: 3-8, Myelo: 0-7, Mono: 1-10.5, nRBC/Promyelo/Meta/Eos: 0-5
RBC Morphology	3	Predominant normocytic normochromic, moderate normocytic hypochromic	Predominantly: Normocytic/Normochromic; Moderate: Microcytosis, Hypochromia; Mild: Anisocytosis, Macrocytosis
Diagnosis	3	chronic lymphocytic leukaemia(prolymphocytic)	Acute Myeloid Leukemia (AML)